Analyzing Brookfield Asset Management (NYSE:BAM) & BR Biopharma (NASDAQ:BRBI)

Brookfield Asset Management (NYSE:BAM) and BR Biopharma (NASDAQ:BRBI) are both finance companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, dividends, risk and institutional ownership.

Insider & Institutional Ownership

68.4% of Brookfield Asset Management shares are held by institutional investors. 29.3% of BR Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Brookfield Asset Management and BR Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Brookfield Asset Management	48.89%	31.50%	15.75%
BR Biopharma	N/A	N/A	N/A

Valuation and Earnings

This table compares Brookfield Asset Management and BR Biopharma”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brookfield Asset Management	$4.82 billion	15.38	$2.48 billion	$1.72	26.28
BR Biopharma	$12.34 billion	0.01	$31.36 million	$0.08	179.39

Brookfield Asset Management has higher earnings, but lower revenue than BR Biopharma. Brookfield Asset Management is trading at a lower price-to-earnings ratio than BR Biopharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings for Brookfield Asset Management and BR Biopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brookfield Asset Management	1	7	7	1	2.50
BR Biopharma	1	0	0	0	1.00

Brookfield Asset Management presently has a consensus target price of $57.03, suggesting a potential upside of 26.15%. Given Brookfield Asset Management’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Brookfield Asset Management is more favorable than BR Biopharma.

Dividends

Brookfield Asset Management pays an annual dividend of $2.01 per share and has a dividend yield of 4.4%. BR Biopharma pays an annual dividend of $0.41 per share and has a dividend yield of 2.9%. Brookfield Asset Management pays out 116.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BR Biopharma pays out 512.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Brookfield Asset Management has raised its dividend for 2 consecutive years. Brookfield Asset Management is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Brookfield Asset Management beats BR Biopharma on 14 of the 17 factors compared between the two stocks.

About Brookfield Asset Management

Brookfield Asset Management Ltd. is a real estate investment firm specializing in alternative asset management services. Its renewable power and transition business includes the operates in the hydroelectric, wind, solar, distributed generation, and sustainable solution sector. The company's infrastructure business engages in the utilities, transport, midstream, and data infrastructure sectors. In addition, its private equity business offers industrial, infrastructure, and business services sectors; and real estate business, which includes housing, logistics, hospitality, science and innovation, office, and retail sectors. Further, it provides credit business; and insurance solution in the reinsurance, annuities, operating platform, and investment solutions sectors. Brookfield Asset Management Ltd. was incorporated in 2022 and is headquartered in Toronto, Canada.

About BR Biopharma

BRBI BR Partners S.A., through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners S.A. is based in S?o Paulo, Brazil.